 |
synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA |
|---|---|
| Trade Name | |
| Orphan Indication | Primary Hyperoxaluria Type 1 |
| USA Market Approval | USA |
| USA Designation Date | 2016-02-08 00:00:00 |
| Sponsor | Alnylam Pharmaceuticals, Inc.;300 Third Street;Cambridge, Massachusetts, 02142 |
